ARQT vs. OCUL, INVA, PHAT, ORIC, NKTX, PBH, MRUS, HCM, IDYA, and FOLD
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Ocular Therapeutix (OCUL), Innoviva (INVA), Phathom Pharmaceuticals (PHAT), ORIC Pharmaceuticals (ORIC), Nkarta (NKTX), Prestige Consumer Healthcare (PBH), Merus (MRUS), HUTCHMED (HCM), IDEAYA Biosciences (IDYA), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.
In the previous week, Ocular Therapeutix had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 6 mentions for Ocular Therapeutix and 3 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.95 beat Ocular Therapeutix's score of 0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.
Ocular Therapeutix received 373 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 69.77% of users gave Ocular Therapeutix an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.
Ocular Therapeutix has lower revenue, but higher earnings than Arcutis Biotherapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Arcutis Biotherapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
59.2% of Ocular Therapeutix shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 5.5% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ocular Therapeutix has a net margin of -192.61% compared to Arcutis Biotherapeutics' net margin of -204.35%. Ocular Therapeutix's return on equity of -76.64% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics currently has a consensus price target of $25.38, indicating a potential upside of 250.48%. Ocular Therapeutix has a consensus price target of $15.17, indicating a potential upside of 207.02%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Ocular Therapeutix.
Summary
Ocular Therapeutix beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
